As per the research reports, the size of the Europe Competent Cells Market is valued at USD 0.26 billion in 2022 and estimated to grow at a CAGR of 9.5%, reaching USD 0.41 billion by 2027 during the forecast period 2022 to 2027.
The competent cells market is also influenced by increased public and private sector expenditure on molecular cloning research and growth in commercial demand for molecular cloned products. Furthermore, rising government initiatives in funding, population expansion, increased healthcare spending, increased product awareness, and an increase in healthcare expenditure all benefit the competent cells market.
In addition, increased governmental and private sector investments and the launch of novel product varieties are expected to bolster the market.
One of the primary factors that drive the growth of the competent cells market is the increase in the R & D activities in the biotechnology sector. In addition, because of the pandemic, viral infections, and increased need for competent cells for creating cloned copies of viral plasmids, the focus on cell cloning activities such as recombinant protein expression and mutagenesis has increased, accelerating the competent cells market growth.
Furthermore, rising funding for DNA cloning technology investigations in academic research institutes and the use of these products in therapies are expected to boost market growth in the near future.
Some constraints could stifle market expansion. However, the extremely high cost of competent cell research and development and market consolidation by a few key players are projected to stifle market expansion over the forecast period.
This research report on the Europe Competent Cells Market has been segmented and sub-segmented into the following categories.
By Type:
By Application:
By End User:
By Country:
Geographically, Europe has the second largest market share in the world, and continued government support in policies and rising demand for cloned products are expected to drive regional market growth over the forecast period.
The U.K Competent Cells Market size is projected to reach significant growth and have a favorable impact on the development of the market, resulting in increased demand for competent cells.
The Germany Competent Cells Market is estimated to grow by increasing research and development on DNA technologies at research institutes. Furthermore, combining artificial intelligence in product development is expected to boost regional market growth.
The France Competent Cells Market is expected to raise its market share during the projection period due to the breakthrough technologies and the need for commercial cloning goods for medicinal purposes.
The Spain Competent Cells Market is expected to grow significantly because of the increasing healthcare and research infrastructure, particularly in this region.
Regionally, aggressive research and development of therapeutic solutions for various ailments and reasonable reimbursement and regulatory conditions are expected to enhance the market in the future years.
Additionally, rising commercial demand for molecularly cloned goods and recombinant proteins and increased government funding in research are expected to propel the market throughout the estimated period.
KEY MARKET PLAYERS
Key players operating in the Europe Competent Cells Market profiled in this report are GCC Biotech (India), SMOBIO Technology (Taiwan), Thermo Fisher Scientific, Inc. (the U.S), QIAGEN N.V. (Germany), OriGene Technologies (U.S.), Merck KGaA (Germany), Promega Corporation (U.S.), Bioline (U.K.), Zymo Research (U.S.), are the leaders in the Europe Competent Cells market.,
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Chemically
5.1.2 Electrocompetent
5.1.3 Y-o-Y Growth Analysis, By Type
5.1.4 Market Attractiveness Analysis, By Type
5.1.5 Market Share Analysis, ByType
5.2 Application
5.2.1 Cloning
5.2.1.1 Subcloning & Routine Cloning
5.2.1.2 Phage Display Library Construction
5.2.1.3 Toxic/Unstable Dna Cloning
5.2.1.4 High-Throughput Cloning
5.2.2 Protein Expression
5.2.3 Other Applications
5.2.3.1 Mutagenesis
5.2.3.2 Large Plasmid Transformation
5.2.3.4 Single-Stranded Dna Production
5.2.3.5 Lentiviral Vector Production
5.2.4 Y-o-Y Growth Analysis, By Application
5.2.5 Market Attractiveness Analysis, By Application
5.2.6 Market Share Analysis, By Application
5.3 End User
5.3.1 Pharmaceutical Companies
5.3.2 Academia
5.3.3 Y-o-Y Growth Analysis, By EndUser
5.3.4 Market Attractiveness Analysis, By EndUser
5.3.5 Market Share Analysis, By EndUser
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By Application
6.1.3.4 By EndUser
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By Application
6.1.4.4 By EndUser
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By Application
6.1.5.4 By EndUser
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 BioDynamics Laboratory, Inc. (Japan)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 GCC Biotech (India)
8.3 SMOBIO Technology (Taiwan)
8.4 Thermo Fisher Scientific, Inc. (U.S)
8.5 QIAGEN N.V. (Germany)
8.6 OriGene Technologies (U.S.)
8.7 Merck KGaA (Germany)
8.8 Promega Corporation (U.S.)
8.9 Bioline (U.K.)
8.10 Zymo Research (U.S.)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
